Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients
- 10 November 2009
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 83 (6), 519-527
- https://doi.org/10.1111/j.1600-0609.2009.01318.x
Abstract
Comorbidity factors have been reported in cancer patients to predict progression free survival (PFS) and overall survival (OS). Renal impairment (RI) is postulated as one negative prognostic factor in multiple myeloma (MM). The study aim was to detect the best way to define RI and the impact of different RI stages on MM outcome. In this multicenter analysis, we determined RI [serum creatinine, estimated glomerular filtration rate (eGFR) by modification of diet in renal disease (MDRD) and Cockcroft-Gault] and other prognostic factors in 198 MM patients to ascertain their value on PFS and OS. Median serum creatinine was 0.9 mg/dL in all patients, whereas the eGFR - being decreased with a median of 80 mL/min/1.73 m(2)- allowed to detect early stages of RI. Via univariate analysis, we observed increasing hazard ratios (HRs) for impaired OS with deteriorating eGFR: with eGFR(MDRD)59 yr as most important variables for OS. By incorporating eGFR<30 as the most relevant factor determined via multivariate analysis and beta(2)-microglobulin (beta(2)-MG) in a novel MM-risk score, we identified patients with significantly differing OS: median survival with 0, 1 or 2 risk factors were 71, 48, and 24 months, respectively. These findings demonstrate that RI is frequent in MM, best detected via eGFR determination and an important prognostic factor. eGFR in combination with beta(2)-MG allows definitive risk stratification with largely differing survival in MM.Keywords
This publication has 30 references indexed in Scilit:
- Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administrationHaematologica, 2009
- Intensive treatment of renal failure in patients with myelomaClinical and Laboratory Haematology, 2008
- Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide dosesEuropean Journal of Haematology, 2008
- Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemiaPublished by American Society of Hematology ,2008
- Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiencesBlood, 2007
- Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myelomaBone Marrow Transplantation, 2007
- 160 years of multiple myeloma: Progress and challengesEuropean Journal Of Cancer, 2006
- State of the art therapy in multiple myeloma and future perspectivesEuropean Journal Of Cancer, 2006
- Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patientsEuropean Journal of Haematology, 1994
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994